About: Hydroxychloroquine safety: A meta-analysis of randomized controlled trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine safety: A meta-analysis of randomized controlled trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials
Creator	Al-Tawfiq, Jaffar Fidsa, Al-Tawfiq, Alireza, Huseein Alireza, Samah Alshehri, Jaffar Alshehri, Samah Eljaaly, Khalid Kasim, ; Kasim, Huseein
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Hydroxychloroquine (HCQ) is currently being examined for COVID-19. No previous meta-analysis has evaluated its side effects versus placebo. We conducted this meta-analysis to compare the safety of HCQ versus placebo. METHODS: Two authors independently searched PubMed and EMBASE databases for randomized controlled trials (RCTs) of adults comparing the adverse events (AEs) of HCQ versus placebo for any indication. Peto odds ratios (Peto ORs) and 95% confidence intervals (CIs) were calculated based on random-effects models. The heterogeneity (I(2)) was assessed using Cochran's Q test. RESULTS: Nine RCTs (eight were double-blind) with a total of 916 patients were included. HCQ caused significantly more skin pigmentation than placebo (Peto OR, 4.64; 95% CI, 1.13 to 19.00; P-value = 0.033; I(2) = 0%). The increase in other AEs did not reach statistical significance: rash (Peto OR, 1.11; 95% CI, 0.3 to 3.77; P-value = 0.03; I(2) = 0%); gastrointestinal AEs (Peto OR, 1.43; 95% CI, 0.55 to 3.72; P-value = 0.46; I(2) = 15.17%); headache (Peto OR, 1.94; 95% CI, 0.65 to 5.78; P-value = 0.23; I(2) = 9.99%); dizziness (Peto OR, 1.32; 95% CI, 0.49 to 3.52; P-value = 0.58; I(2) = 0%); fatigue (Peto OR, 2.13; 95% CI, 0.76 to 5.98; P-value = 0.15; I(2) = 0%); and visual AEs (Peto OR, 1.61; 95% CI, 0.76 to 3.41; P-value = 0.22; I(2) = 0%). Cardiac toxicity was not reported. CONCLUSIONS: This meta-analysis of RCTs found a significantly higher risk of skin pigmentation in HCQ users versus placebo. More data are needed to evaluate HCQ in the context of COVID-19 treatment.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1016/j.tmaid.2020.101812
bibo:pmid	32645478
has license	no-cc
sha1sum (hex)	14f0cb42904327baf26e76c849435f22bc654f95
schema:url	https://doi.org/10.1016/j.tmaid.2020.101812
resource representing a document's title	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials
has PubMed Central identifier	PMC7342171
has PubMed identifier	32645478
schema:publication	Travel Med Infect Dis
resource representing a document's body	covid:14f0cb42904327baf26e76c849435f22bc654f95#body_text
is schema:about of	named entity 'randomized controlled trials' named entity 'requests' named entity 'Randomized' named entity 'safety' named entity 'BACKGROUND' covid:arg/14f0cb42904327baf26e76c849435f22bc654f95 named entity 'compare' named entity 'Corresponding' named entity 'author' named entity 'Trials' named entity 'HCQ' named entity 'meta-analysis' named entity 'HCQ' named entity 'Skin pigmentation' named entity 'adverse reactions' named entity 'cardiac toxicity' named entity 'bibliographic databases' named entity 'CHQ' named entity 'poor metabolizer' named entity 'drug companies' named entity 'skin pigmentation' named entity 'antiviral activity' named entity 'risk factors' named entity 'HCQ' named entity 'HCQ' named entity 'long-term' named entity 'chloroquine' named entity 'metaanalysis' named entity 'CYP2D6' named entity 'hydroxylated' named entity 'adverse reactions' named entity 'QTc interval' named entity 'Systematic Reviews' named entity 'autoimmune diseases' named entity 'meta-analysis' named entity 'ECG monitoring' named entity 'half-life' named entity 'Coronavirus Disease 2019' named entity 'skin rash' named entity 'antimalarial drugs' named entity 'gums' named entity 'Cochrane' named entity 'single-blind' named entity 'meta-analysis' named entity 'Toll like receptor' named entity 'prophylaxis' named entity 'Englewood, NJ' named entity 'QTc' named entity 'placebo' named entity 'QT prolongation' named entity 'lopinavir' named entity 'phenotype' named entity 'toxicity' named entity 'HCQ' named entity 'AEs' named entity 'coagulopathies' named entity 'AEs' named entity 'presentation of antigens' named entity 'skin pigmentation' named entity 'cutaneous lupus erythematosus' named entity 'analog' named entity 'CYP2D6' named entity 'short duration' named entity 'AEs' named entity 'Cochrane Library' named entity 'endocrine diseases' named entity 'meta-analysis' named entity 'AEs' named entity 'HCQ' named entity 'RCTs' named entity 'hepatic' named entity 'HCQ'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software